Strategic IP moat Strong worldwide patent protection for the Full Sense Bariatric Device in key markets (US, EU, Australia, China, Russia) suggests a defensible product position and potential competitive advantage that can be leveraged in conversations with investors, partners, and potential distributors seeking a novel obesity treatment.

Clinical progress signals Preclinical success and implantation in over 50 patients with zero non-responders and superior excess weight loss vs gastric bypass or banding indicate a compelling efficacy narrative that can be highlighted to drive inquiries from medical centers, health systems, and obesity-focused clinics.

Regulatory and market readiness Global market coverage and pending reviews imply near-term expansion opportunities; sales outreach can target international distributors, contract research organizations, and regulatory consultants to accelerate trials and commercial timelines in priority regions.

Funding and growth potential Current funding of $14M and recent financing activity position the company for larger clinical trials and scale; prospecting for strategic investors, grant programs, and partnerships with hospital systems or device manufacturers can unlock capital for commercialization.

Technology and data edge Adoption of modern tech stack and strong digital footprint (AWS, analytics, patient feedback platforms) supports a data-driven go-to-market approach; leverage digital marketing, clinician education portals, and outcome tracking collaborations to drive adoption and trust among providers.